Company: SYRA
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0001493152-25-009873
Chunk: 184

Company: Syra Health Corp
Filing Date: 2025-03-11
Form: 10-K
Item: Item 1
Chunk 184
---
 and protect those rights, which would divert management resources, could
be expensive and may not effectively protect our intellectual property. Even if we establish infringement, a court may decide not to
grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate
remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there
is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive
these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, there can
be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims. Even if we ultimately
prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel
could outweigh any benefit we receive as a result of the proceedings. As a result, if we fail to maintain adequate intellectual property
protection or if a third party infringes or misappropriates our intellectual property, it may have a material adverse impact on our business,
results of operations or financial condition.

-18-

Many
of our products are based on or incorporate proprietary information. We actively seek to protect our proprietary information, including
our trade secrets and proprietary know-how, by generally requiring our employees, consultants, other advisors and other third parties
to execute agreements that contain confidentiality provisions. Despite these efforts and precautions, we may be unable to prevent a third
party from copying or otherwise obtaining and using our trade secrets or our other intellectual property without authorization and legal
remedies may not adequately compensate us for the damages caused by such unauthorized use.

In
addition, there can be no assurance that our competitors will not independently develop products or services that are equivalent or superior
to our solutions.

We
may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information
of third parties.

We
have received confidential and proprietary information from third parties. In addition, we may employ individuals who were previously
employed at other healthcare services companies. We may be subject to claims that we or our employees, consultants or independent contractors
have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees’
former employers. Further, we may be subject